TrialBreast cancer research : BCR2021

Abemaciclib plus fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in premenopausal women: subgroup analysis from the MONARCH 2 trial.

Patrick Neven et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.